Literature DB >> 1793021

15-Deoxyspergualin (15-DOS) has a curative effect on the development of SLE-like autoimmune disease in MRL/1 mice.

H U Schorlemmer1, R R Bartlett, F R Seiler.   

Abstract

Treating MRL/1pr mice, which spontaneously develop systemic lupus erythematosus and rheumatoid arthritis, with 15-DOS resulted in a decrease in the amount of autoantibodies and inhibited proteinuria of the developing glomerulonephritis with an improved survival rate of these autoimmune mice. 15-DOS treatment also lowered the percentage of animals with swollen lymph nodes and inhibited the development of splenomegaly. In the established disease 15-DOS returned urine-protein values and renal function (serum urea and creatinine) to normal levels. Circulating rheumatoid factor and autoantibodies to double-stranded DNA were reduced and the increase in paw volume (signs of a polyarthritis) was inhibited.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1793021     DOI: 10.1007/bf01993264

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  2 in total

1.  Synthesis of (-)-15-deoxyspergualin and (-)-spergualin-15-phosphate.

Authors:  H Iwasawa; S Kondo; D Ikeda; T Takeuchi; H Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1982-12       Impact factor: 2.649

2.  Autoreactivity to collagen in a murine lupus model.

Authors:  K Phadke; R Fouts; J Parrish; R S Baker
Journal:  Arthritis Rheum       Date:  1984-03
  2 in total
  1 in total

1.  Phase II study of deoxyspergualin in metastatic breast cancer.

Authors:  K Dhingra; V Valero; L Gutierrez; R Theriault; D Booser; F Holmes; A Buzdar; G Fraschini; G Hortobagyi
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.